Current and Emerging Therapies for Atherosclerotic Cardiovascular Disease Risk Reduction in Hypertriglyceridemia
Hypertriglyceridemia (HTG) is a prevalent medical condition in patients with cardiometabolic risk factors and is associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD), if left undiagnosed and undertreated. Current guidelines identify HTG as a risk-enhancing factor and,...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/12/4/1382 |
| _version_ | 1797620209951965184 |
|---|---|
| author | Reed Mszar Sarah Bart Alexander Sakers Daniel Soffer Dean G. Karalis |
| author_facet | Reed Mszar Sarah Bart Alexander Sakers Daniel Soffer Dean G. Karalis |
| author_sort | Reed Mszar |
| collection | DOAJ |
| description | Hypertriglyceridemia (HTG) is a prevalent medical condition in patients with cardiometabolic risk factors and is associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD), if left undiagnosed and undertreated. Current guidelines identify HTG as a risk-enhancing factor and, as a result, recommend clinical evaluation and lifestyle-based interventions to address potential secondary causes of elevated triglyceride (TG) levels. For individuals with mild to moderate HTG at risk of ASCVD, statin therapy alone or in combination with other lipid-lowering medications known to decrease ASCVD risk are guideline-endorsed. In addition to lifestyle modifications, patients with severe HTG at risk of acute pancreatitis may benefit from fibrates, mixed formulation omega-3 fatty acids, and niacin; however, evidence does not support their use for ASCVD risk reduction in the contemporary statin era. Novel therapeutics including those that target apoC-III and ANGPTL3 have shown to be safe, well-tolerated, and effective for lowering TG levels. Given the growing burden of cardiometabolic disease and risk factors, public health and health policy strategies are urgently needed to enhance access to effective pharmacotherapies, affordable and nutritious food options, and timely health care services. |
| first_indexed | 2024-03-11T08:38:53Z |
| format | Article |
| id | doaj.art-9d7f8b46338f43a0b79298c5464ece42 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-11T08:38:53Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-9d7f8b46338f43a0b79298c5464ece422023-11-16T21:18:46ZengMDPI AGJournal of Clinical Medicine2077-03832023-02-01124138210.3390/jcm12041382Current and Emerging Therapies for Atherosclerotic Cardiovascular Disease Risk Reduction in HypertriglyceridemiaReed Mszar0Sarah Bart1Alexander Sakers2Daniel Soffer3Dean G. Karalis4Department of Physiology, Georgetown University, Washington, DC 20057, USAFrank H. Netter MD School of Medicine, Quinnipiac University, North Haven, CT 06473, USADepartment of Medicine, Massachusetts General Hospital, Boston, MA 02114, USAPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USADepartment of Cardiology, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USAHypertriglyceridemia (HTG) is a prevalent medical condition in patients with cardiometabolic risk factors and is associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD), if left undiagnosed and undertreated. Current guidelines identify HTG as a risk-enhancing factor and, as a result, recommend clinical evaluation and lifestyle-based interventions to address potential secondary causes of elevated triglyceride (TG) levels. For individuals with mild to moderate HTG at risk of ASCVD, statin therapy alone or in combination with other lipid-lowering medications known to decrease ASCVD risk are guideline-endorsed. In addition to lifestyle modifications, patients with severe HTG at risk of acute pancreatitis may benefit from fibrates, mixed formulation omega-3 fatty acids, and niacin; however, evidence does not support their use for ASCVD risk reduction in the contemporary statin era. Novel therapeutics including those that target apoC-III and ANGPTL3 have shown to be safe, well-tolerated, and effective for lowering TG levels. Given the growing burden of cardiometabolic disease and risk factors, public health and health policy strategies are urgently needed to enhance access to effective pharmacotherapies, affordable and nutritious food options, and timely health care services.https://www.mdpi.com/2077-0383/12/4/1382fibrateslipidslipoproteinsniacinomega-3 fatty acidsstatins |
| spellingShingle | Reed Mszar Sarah Bart Alexander Sakers Daniel Soffer Dean G. Karalis Current and Emerging Therapies for Atherosclerotic Cardiovascular Disease Risk Reduction in Hypertriglyceridemia Journal of Clinical Medicine fibrates lipids lipoproteins niacin omega-3 fatty acids statins |
| title | Current and Emerging Therapies for Atherosclerotic Cardiovascular Disease Risk Reduction in Hypertriglyceridemia |
| title_full | Current and Emerging Therapies for Atherosclerotic Cardiovascular Disease Risk Reduction in Hypertriglyceridemia |
| title_fullStr | Current and Emerging Therapies for Atherosclerotic Cardiovascular Disease Risk Reduction in Hypertriglyceridemia |
| title_full_unstemmed | Current and Emerging Therapies for Atherosclerotic Cardiovascular Disease Risk Reduction in Hypertriglyceridemia |
| title_short | Current and Emerging Therapies for Atherosclerotic Cardiovascular Disease Risk Reduction in Hypertriglyceridemia |
| title_sort | current and emerging therapies for atherosclerotic cardiovascular disease risk reduction in hypertriglyceridemia |
| topic | fibrates lipids lipoproteins niacin omega-3 fatty acids statins |
| url | https://www.mdpi.com/2077-0383/12/4/1382 |
| work_keys_str_mv | AT reedmszar currentandemergingtherapiesforatheroscleroticcardiovasculardiseaseriskreductioninhypertriglyceridemia AT sarahbart currentandemergingtherapiesforatheroscleroticcardiovasculardiseaseriskreductioninhypertriglyceridemia AT alexandersakers currentandemergingtherapiesforatheroscleroticcardiovasculardiseaseriskreductioninhypertriglyceridemia AT danielsoffer currentandemergingtherapiesforatheroscleroticcardiovasculardiseaseriskreductioninhypertriglyceridemia AT deangkaralis currentandemergingtherapiesforatheroscleroticcardiovasculardiseaseriskreductioninhypertriglyceridemia |